Liquid Biopsy in Colorectal Cancer: No Longer Young, but Not Yet Old

Overview

Journal World J Gastroenterol

Publisher Baishideng Publishing Group

Specialty Gastroenterology

Date 2022 May 18

PMID 35582130

Authors

Giandomenico Roviello

Daniele Lavacchi

Lorenzo Antonuzzo

Martina Catalano

Enrico Mini

Affiliations

Soon will be listed here.

Abstract

Colorectal cancer (CRC) is one of the most prevalent cancers and the second leading cause of cancer-related deaths worldwide. The treatment strategy employed in CRC patients is becoming highly dependent on molecular characteristics present at diagnosis and during treatment. Liquid biopsy is an emerging field in the management of this cancer, and its relevance as a potential diagnostic, prognostic, monitoring, and therapeutic tool makes it a viable strategy in the clinical management of CRC patients. Liquid biopsy also has certain limitations, but these limitations seem to be at the reach of near-future technological development. In this letter, we focus on the clinical perspectives of liquid biopsy in CRC with particular regard to the various biomarkers recently identified that have been shown to be potentially useful in multiple aspects of early stage or metastatic CRC.

Citing Articles

Circulating tumor DNA in liquid biopsy: Current diagnostic limitation.

Liu S World J Gastroenterol. 2024; 30(15):2175-2178.

PMID: 38681986 PMC: 11045476. DOI: 10.3748/wjg.v30.i15.2175.

Early changes in circulating tumor DNA (ctDNA) predict treatment response in metastatic KRAS-mutated colorectal cancer (mCRC) patients.

Lavacchi D, Gelmini S, Calabri A, Rossi G, Simi L, Caliman E Heliyon. 2023; 9(11):e21853.

PMID: 38027900 PMC: 10663919. DOI: 10.1016/j.heliyon.2023.e21853.

DNA repair deficiency as circulating biomarker in prostate cancer.

Catalano M, Generali D, Gatti M, Riboli B, Paganini L, Nesi G Front Oncol. 2023; 13:1115241.

PMID: 36793600 PMC: 9922904. DOI: 10.3389/fonc.2023.1115241.

Mutations matter: An observational study of the prognostic and predictive value of KRAS mutations in metastatic colorectal cancer.

Lavacchi D, Fancelli S, Roviello G, Castiglione F, Caliman E, Rossi G Front Oncol. 2022; 12:1055019.

PMID: 36523988 PMC: 9745189. DOI: 10.3389/fonc.2022.1055019.

References

Salvianti F, Gelmini S, Mancini I, Pazzagli M, Pillozzi S, Giommoni E . Circulating tumour cells and cell-free DNA as a prognostic factor in metastatic colorectal cancer: the OMITERC prospective study. Br J Cancer. 2021; 125(1):94-100. PMC: 8257609. DOI: 10.1038/s41416-021-01399-6. View

Sun G, Meng J, Duan H, Zhang D, Tang Y . Diagnostic Assessment of septin9 DNA Methylation for Colorectal Cancer Using Blood Detection: A Meta-Analysis. Pathol Oncol Res. 2018; 25(4):1525-1534. DOI: 10.1007/s12253-018-0559-5. View

Zhou B, Xu K, Zheng X, Chen T, Wang J, Song Y . Application of exosomes as liquid biopsy in clinical diagnosis. Signal Transduct Target Ther. 2020; 5(1):144. PMC: 7400738. DOI: 10.1038/s41392-020-00258-9. View

Sastre J, Maestro M, Puente J, Veganzones S, Alfonso R, Rafael S . Circulating tumor cells in colorectal cancer: correlation with clinical and pathological variables. Ann Oncol. 2008; 19(5):935-8. DOI: 10.1093/annonc/mdm583. View

Roviello G, DAngelo A, Petrioli R, Roviello F, Cianchi F, Nobili S . Encorafenib, Binimetinib, and Cetuximab in BRAF V600E-Mutated Colorectal Cancer. Transl Oncol. 2020; 13(9):100795. PMC: 7260582. DOI: 10.1016/j.tranon.2020.100795. View

deVos T, Tetzner R, Model F, Weiss G, Schuster M, Distler J . Circulating methylated SEPT9 DNA in plasma is a biomarker for colorectal cancer. Clin Chem. 2009; 55(7):1337-46. DOI: 10.1373/clinchem.2008.115808. View

Matsumura T, Sugimachi K, Iinuma H, Takahashi Y, Kurashige J, Sawada G . Exosomal microRNA in serum is a novel biomarker of recurrence in human colorectal cancer. Br J Cancer. 2015; 113(2):275-81. PMC: 4506387. DOI: 10.1038/bjc.2015.201. View

Xie Y, Chen Y, Fang J . Comprehensive review of targeted therapy for colorectal cancer. Signal Transduct Target Ther. 2020; 5(1):22. PMC: 7082344. DOI: 10.1038/s41392-020-0116-z. View

Cai Z, Wang Z, Liu C, Shi D, Li D, Zheng M . Detection of Microsatellite Instability from Circulating Tumor DNA by Targeted Deep Sequencing. J Mol Diagn. 2020; 22(7):860-870. DOI: 10.1016/j.jmoldx.2020.04.210. View

10.

Gandara D, Paul S, Kowanetz M, Schleifman E, Zou W, Li Y . Blood-based tumor mutational burden as a predictor of clinical benefit in non-small-cell lung cancer patients treated with atezolizumab. Nat Med. 2018; 24(9):1441-1448. DOI: 10.1038/s41591-018-0134-3. View

11.

Vesterman Henriksen T, Tarazona N, Frydendahl A, Reinert T, Gimeno-Valiente F, Carbonell-Asins J . Circulating Tumor DNA in Stage III Colorectal Cancer, beyond Minimal Residual Disease Detection, toward Assessment of Adjuvant Therapy Efficacy and Clinical Behavior of Recurrences. Clin Cancer Res. 2021; 28(3):507-517. PMC: 9401484. DOI: 10.1158/1078-0432.CCR-21-2404. View

12.

Parkinson D, Dracopoli N, Petty B, Compton C, Cristofanilli M, Deisseroth A . Considerations in the development of circulating tumor cell technology for clinical use. J Transl Med. 2012; 10:138. PMC: 3478228. DOI: 10.1186/1479-5876-10-138. View

13.

Ignatiadis M, Sledge G, Jeffrey S . Liquid biopsy enters the clinic - implementation issues and future challenges. Nat Rev Clin Oncol. 2021; 18(5):297-312. DOI: 10.1038/s41571-020-00457-x. View

14.

Bando H, Kagawa Y, Kato T, Akagi K, Denda T, Nishina T . A multicentre, prospective study of plasma circulating tumour DNA test for detecting RAS mutation in patients with metastatic colorectal cancer. Br J Cancer. 2019; 120(10):982-986. PMC: 6734650. DOI: 10.1038/s41416-019-0457-y. View

15.

Lavacchi D, Roviello G, DAngelo A . Tumor-Agnostic Treatment for Cancer: When How is Better than Where. Clin Drug Investig. 2020; 40(6):519-527. DOI: 10.1007/s40261-020-00915-5. View

16.

Galamb O, Bartak B, Kalmar A, Nagy Z, Szigeti K, Tulassay Z . Diagnostic and prognostic potential of tissue and circulating long non-coding RNAs in colorectal tumors. World J Gastroenterol. 2019; 25(34):5026-5048. PMC: 6747286. DOI: 10.3748/wjg.v25.i34.5026. View

17.

Dong L, Lin W, Qi P, Xu M, Wu X, Ni S . Circulating Long RNAs in Serum Extracellular Vesicles: Their Characterization and Potential Application as Biomarkers for Diagnosis of Colorectal Cancer. Cancer Epidemiol Biomarkers Prev. 2016; 25(7):1158-66. DOI: 10.1158/1055-9965.EPI-16-0006. View

18.

Cremolini C, Rossini D, DellAquila E, Lonardi S, Conca E, Del Re M . Rechallenge for Patients With RAS and BRAF Wild-Type Metastatic Colorectal Cancer With Acquired Resistance to First-line Cetuximab and Irinotecan: A Phase 2 Single-Arm Clinical Trial. JAMA Oncol. 2018; 5(3):343-350. PMC: 6439839. DOI: 10.1001/jamaoncol.2018.5080. View

19.

Potter N, Hurban P, White M, Whitlock K, Lofton-Day C, Tetzner R . Validation of a real-time PCR-based qualitative assay for the detection of methylated SEPT9 DNA in human plasma. Clin Chem. 2014; 60(9):1183-91. DOI: 10.1373/clinchem.2013.221044. View

20.

Silva J, Garcia V, Rodriguez M, Compte M, Cisneros E, Veguillas P . Analysis of exosome release and its prognostic value in human colorectal cancer. Genes Chromosomes Cancer. 2012; 51(4):409-18. DOI: 10.1002/gcc.21926. View